Abstract
Cardiovascular (CV) diseases are caused by vascular dysfunction. The enhanced sensitivity to vasoconstrictors, reduced endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH) indicate CV dysfunction. In recent years, recombinant human relaxin, known as serelaxin, has emerged as a new vasoactive drug that is useful in acute heart failure. First part of this review article encompasses the role of endogenous relaxin in CV homeostasis. Subsequently, vascular effects of serelaxin and the underlying modes of action in comparison to other vasodilators are discussed. Finally, the usefulness of treatment with serelaxin in vascular dysfunction in different CV diseases, particularly due to oxidative stress, is explained.
Keywords: Recombinant human relaxin, acute heart failure, cardiovascular, endothelium-derived hyperpolarization, homeostasis, nitric oxide, prostacyclin, vasoconstrictors.
Graphical Abstract
Current Protein & Peptide Science
Title:Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction
Volume: 19 Issue: 11
Author(s): Ghulam Murtaza*, Adeel Siddiqui and Izhar Hussain
Affiliation:
- Department of Pharmacy, COMSATS University Islamabad, Lahore Campus,Pakistan
Keywords: Recombinant human relaxin, acute heart failure, cardiovascular, endothelium-derived hyperpolarization, homeostasis, nitric oxide, prostacyclin, vasoconstrictors.
Abstract: Cardiovascular (CV) diseases are caused by vascular dysfunction. The enhanced sensitivity to vasoconstrictors, reduced endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH) indicate CV dysfunction. In recent years, recombinant human relaxin, known as serelaxin, has emerged as a new vasoactive drug that is useful in acute heart failure. First part of this review article encompasses the role of endogenous relaxin in CV homeostasis. Subsequently, vascular effects of serelaxin and the underlying modes of action in comparison to other vasodilators are discussed. Finally, the usefulness of treatment with serelaxin in vascular dysfunction in different CV diseases, particularly due to oxidative stress, is explained.
Export Options
About this article
Cite this article as:
Murtaza Ghulam *, Siddiqui Adeel and Hussain Izhar , Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction, Current Protein & Peptide Science 2018; 19 (11) . https://dx.doi.org/10.2174/1389203719666180709103020
DOI https://dx.doi.org/10.2174/1389203719666180709103020 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Analgesic Effects of Opioids: Opioids and the Endocrine System
Current Pharmaceutical Design New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis
MicroRNA The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Expression of the Cold Shock Protein RNA Binding Motif Protein 3 is Transcriptionally Responsive to Organ Temperature in Mice
Protein & Peptide Letters p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice
Current Vascular Pharmacology New Perspectives on Acetaminophen
Current Cardiology Reviews Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Targets for Medical Therapy to Limit Abdominal Aortic Aneurysm Progression
Current Drug Targets Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design Oxidative Stress, Antioxidants, and Endothelial Function
Current Medicinal Chemistry